 | | Vol. 22.30 – 23 August, 2021 |
| |
|
|
| Optically clear immunocompromised zebrafish were engrafted with fluorescent-labeled human cancers along with CAR T cells, bispecific T cell engagers, and antibody peptide epitope conjugates, allowing real-time single-cell visualization of T cell–based immunotherapies in vivo.
[Journal of Experimental Medicine] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists used genetic engineering to create human pluripotent stem cells in which the majority of the polymorphic human leukocyte antigens, the main drivers of allogeneic rejection, were deleted.
[Cell Reports] |
|
|
|
| Allogeneic, bone marrow-derived mesenchymal stem cells were systemically administered into patients with stable chronic obstructive pulmonary disease. Gene expression profiles from peripheral blood mononuclear cells were analyzed across the first week after infusion.
[Stem Cells Translational Medicine] |
|
|
|
| To rescue T and NK cells after UCART7, researchers created hematopoietic stem cells (HSCs) genetically deleted for CD7. CD7-KO HSCs were able to engraft immunodeficient mice and differentiate into T and NK cells lacking CD7 expression.
[JCI Insight] |
|
|
|
| The antitumour activity of lenvatinib in immunocompetent and immunodeficient mice was compared to determine the role of T cell immunity. The antitumour activity of T cells was analysed by cytokine production and adoptive T cell therapy.
[Pharmacological Research] |
|
|
|
| Researchers found that the ex vivo expanded mesenchymal stem cells showed activated p38 mitogen-activated protein kinase p38 (MAPK) signaling and exhibited increased oxidative stress.
[Stem Cell Reviews and Reports] |
|
|
|
| Coinjections of endothelial progenitor cells plus mesenchymal stem cells significantly enhanced the survival rate of lipopolysaccharide-induced mice, decreased concentrations of pro-inflammatory cytokines, and increased the level of anti-inflammatory cytokine.
[Journal of Cellular Biochemistry] |
|
|
|
| Investigators showed that intramuscular injection of placental (P)-MSCs homed more towards the visceral site, restored HOMA-IR and glucose homeostasis in the WNIN/GR-Ob rats. P-MSC therapy was effective in re-establishing the dysregulated cytokines.
[Scientific Reports] |
|
|
|
| Graft-versus-host disease (GVHD) was induced in lethally irradiated BALB/c mice. M2 macrophages derived from donor bone marrow (BM) were administered intravenously, while controls received donor BM-mononuclear cells and splenocytes.
[Immunity Inflammation and Disease] |
|  |
|
|
|
| CAR-T cell therapy has shown more efficiency in cancer treatment, particularly regarding blood cancers. The expression of specific markers such as TAAs on CSCs in varied cancer types makes them as potent tools for CAR-T cell therapy.
[Acta Pharmaceutica Sinica B] |
|
|
|
| Scientists summarize the current knowledge about statins and other agents used as endothelial protectants. They propose further studies using statins for prophylaxis and prevention of end-organ damage related to extensive endothelial dysfunction in hematopoietic stem cell transplantation and chimeric antigen receptor-T cells.
[Blood Reviews] |
|
|
|
| The association between hematopoietic stem-cell transplantation and early- and late-onset cardiotoxicity remains controversial as these cardiac complications, including acute heart failure and arrhythmia, such as atrial fibrillation, can occasionally be lethal.
[Bone Marrow Transplantation] |
|
|
|
|
| Genevant Sciences Corporation, a leading nucleic acid delivery company with world-class platforms and the industry’s most robust and expansive lipid nanoparticle patent estate, announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited for the development and commercialization of novel nonviral gene therapies to treat up to two undisclosed rare liver diseases.
[Genevant Sciences Corporation] |
|
|
|
| Bristol Myers Squibb announced that the FDA has accepted its supplemental Biologics License Application for Orencia for the prevention of moderate to severe aGvHD in patients six years of age and older receiving unrelated donor hematopoietic stem cell transplantation.
[Bristol Myers Squibb] |
|
|
|
|
| November 22 – 23, 2021
Ghent, Belgium |
|
|
|
|
|
| | Epitopea – Cambridge, England, United Kingdom |
|
|
|
| | Danaher – Toronto, Ontario, Canada |
|
|
|
| | University Of Wisconsin–Madison – Madison, Wisconsin, United States |
|
|
|
| | University Medical Center Utrecht – Utrecht, Netherlands |
|
|
|
| | The Geneva Foundation – Tacoma, Washington, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
